Microcap Decliners: Republic Airways Holdings Inc. (NASDAQ:RJET), Unilife Corporation (NASDAQ:UNIS), VIVUS Inc. (NASDAQ:VVUS), Immunomedics Inc. (NASDAQ:IMMU), Corium International, Inc. (NASDAQ:CORI)

On 27 July, Republic Airways Holdings Inc. (NASDAQ: RJET) said it expects to report second quarter net income of USD4.0 to USD5.0 million or USD0.08 to USD0.10 per diluted share, and pretax margins of 2.5 percent to 3.0 percent on operating revenues of USD338 to USD340 million. Republic Airways Holdings Inc. (NASDAQ:RJET) belongs to Services sector. Its net profit margin is 4.10% and weekly performance is -15.78%. On last trading day company shares ended up $3.79. Republic Airways Holdings Inc. (NASDAQ:RJET) distance from 50-day simple moving average (SMA50) is -57.10%.

On 29 July, Unilife Corporation (NASDAQ:UNIS) announced the implementation of a multifaceted financing strategy that provides the Company with flexibility and control to support its continued business growth. Unilife Corporation (NASDAQ:UNIS) shares moved down -7.05% in last trading session and ended the day at $1.45. UNIS return on assets is -87.00%. Unilife Corporation (NASDAQ:UNIS) quarterly performance is -55.38%.

On 30 July, VIVUS Inc. (NASDAQ:VVUS) reported Total revenue was $23.0 million in the current quarter, compared to $21.9 million in the second quarter of 2014. Of the total revenue, net product revenue was $14.0 million from sales of Qsymia in the current quarter, compared to $11.0 million in the second quarter of 2014.On 06 August, VIVUS Inc. (NASDAQ:VVUS) shares moved down -10.00% and was closed at $1.17. VVUS EPS growth in last 5 year was -1.80%. VIVUS Inc. (NASDAQ:VVUS) year to date (YTD) performance is -59.38%.

On 4 August, Immunomedics, Inc. (NASDAQ:IMMU) announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the Company’s humanized anti-CD20 antibody, for the treatment of immune thrombocytopenia (ITP).Immunomedics Inc. (NASDAQ:IMMU) ended the last trading day at $1.88. Company weekly volatility is calculated as 6.89% and price to cash ratio as 1.65. Immunomedics Inc. (NASDAQ:IMMU) showed a weekly performance of -10.90%.

Corium International, Inc. (NASDAQ:CORI) announced the pricing of its underwritten public offering of 4,000,000 shares of common stock at a public offering price of $13.00 per share. Gross proceeds to Corium from this offering are expected to be approximately $52 million. Corium intends to use the net proceeds from this offering for general corporate purposes, which may include funding research and development, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to its own, and capital expenditures. Corium International, Inc. (NASDAQ:CORI) shares moved down -9.23% in last trading session and ended the day at $12.10. CORI Gross Margin is 17.60% and its return on assets is -40.80%. Corium International, Inc. (NASDAQ:CORI) quarterly performance is 21.12%.

Leave a Reply

Your email address will not be published. Required fields are marked *